Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment

被引:61
|
作者
Elkins, Ryan C. [1 ]
Davies, Mark R. [2 ]
Brough, Stephen J. [3 ]
Gavaghan, David J. [4 ]
Cui, Yi [5 ]
Abi-Gerges, Najah [1 ]
Mirams, Gary R. [4 ]
机构
[1] AstraZeneca, Global Safety Assessment, Global Safety Pharmacol, Macclesfield SK10 4TG, Cheshire, England
[2] AstraZeneca, R&D Informat, Clin Informat, Macclesfield SK10 4TG, Cheshire, England
[3] GlaxoSmithKline, Screening & Compound Profiling, Stevenage SG1 2NY, Herts, England
[4] Univ Oxford, Dept Comp Sci, Oxford OX1 3QD, England
[5] GlaxoSmithKline, Safety Assessment, Safety Pharmacol, Ware SG12 0DP, Herts, England
基金
英国工程与自然科学研究理事会; 英国国家替代、减少和改良动物研究中心;
关键词
High-throughput; Compound screening; Variability; Uncertainty; Cardiac safety; Action potential; Mathematical model; CELLULAR ELECTROPHYSIOLOGY MODELS; IONWORKS(TM) HT; ASSAY; HERG; OPTIMIZATION; PROLONGATION; VALIDATION; SIMULATION; RISK;
D O I
10.1016/j.vascn.2013.04.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Unwanted drug interactions with ionic currents in the heart can lead to an increased proarrhythmic risk to patients in the clinic. It is therefore a priority for safety pharmacology teams to detect block of cardiac ion channels, and new technologies have enabled the development of automated and high-throughput screening assays using cell lines. As a result of screening multiple ion-channels there is a need to integrate information, particularly for compounds affecting more than one current, and mathematical electrophysiology in-silico action potential models are beginning to be used for this. Methods: We quantified the variability associated with concentration-effect curves fitted to recordings from high-throughput Molecular Devices IonWorks (R) Quattro (TM) screens when detecting block of I-Kr (hERG), I-Na (NaV1.5), I-CaL (CaV1.2), I-Ks (KCNQ1/minK) and I-to (Kv4.3/KChIP2.2), and the Molecular Devices FLIPR (R) Tetra fluorescence screen for I-CaL (CaV1.2), for control compounds used at AstraZeneca and GlaxoSmithKline. We examined how screening variability propagates through in-silico action potential models for whole cell electrical behaviour, and how confidence intervals on model predictions can be estimated with repeated simulations. Results: There are significant levels of variability associated with high-throughput ion channel electrophysiology screens. This variability is of a similar magnitude for different cardiac ion currents and different compounds. Uncertainty in the Hill coefficients of reported concentration-effect curves is particularly high. Depending on a compound's ion channel blocking profile, the uncertainty introduced into whole-cell predictions can become significant. Discussion: Our technique allows confidence intervals to be placed on computational model predictions that are based on high-throughput ion channel screens. This allows us to suggest when repeated screens should be performed to reduce uncertainty in a compound's action to acceptable levels, to allow a meaningful interpretation of the data. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:112 / 122
页数:11
相关论文
共 50 条
  • [1] High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology
    Dunlop, John
    Bowlby, Mark
    Peri, Ravikumar
    Vasilyev, Dmytro
    Arias, Robert
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (04) : 358 - 368
  • [2] High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology
    John Dunlop
    Mark Bowlby
    Ravikumar Peri
    Dmytro Vasilyev
    Robert Arias
    [J]. Nature Reviews Drug Discovery, 2008, 7 : 358 - 368
  • [3] Web-based simulation and analysis tool for high-throughput ion-channel screening data
    Fernandez, Eric
    Mistry, Hitesh
    Brightman, Frances
    Orrell, David
    Guest, Deborah
    Swinton, Jonathan
    Chassagnole, Christophe
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2015, 75 : 170 - 170
  • [4] High-throughput screening for ion channel modulators
    Falconer, M
    Smith, F
    Surah-Narwal, S
    Congrave, G
    Liu, Z
    Hayter, P
    Ciaramella, G
    Keighley, W
    Haddock, P
    Waldron, G
    Sewing, A
    [J]. JOURNAL OF BIOMOLECULAR SCREENING, 2002, 7 (05) : 460 - 465
  • [5] An Automatic Offset Correction Platform for High-Throughput Ion-Channel Electrophysiology
    Thei, F.
    Rossi, M.
    Bennati, M.
    Crescentini, M.
    Tartagni, M.
    [J]. EUROSENSORS XXIV CONFERENCE, 2010, 5 : 816 - 819
  • [6] High-throughput for cardiac ion screening strategies channels
    Numann, R
    Negulescu, PA
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2001, 11 (02) : 54 - 59
  • [7] High-throughput Ion Channel Screening: A "Patch"-work Solution
    Perkel, Jeffrey M.
    [J]. BIOTECHNIQUES, 2010, 48 (01) : 25 - 29
  • [8] Higher-throughput automated systems for ion-channel screening
    Senior, K
    [J]. DRUG DISCOVERY TODAY, 2000, 5 (12) : S56 - S58
  • [9] High-throughput screening of human ion channel genes in common neurological disorders
    Lafreniere, RG
    Simoneau, M
    Gupta, N
    Boisvert, K
    Lafreniere, F
    Poulin, JF
    Laurent, S
    Albanese, M
    Charles, MK
    Silveira, I
    Turecki, G
    Alda, M
    Chouinard, S
    Brais, B
    Rouleau, GA
    [J]. ANNALS OF NEUROLOGY, 2005, 58 : S24 - S24
  • [10] Exploiting high-throughput ion channel screening technologies in integrated drug discovery
    Treherne, JM
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (04) : 397 - 406